Select publications
Adam R et al. Chemotherapy and surgery in the treatment of colorectal liver metastases: The golden alliance. Gastrointestinal Cancer Symposium 2007;Educational summaries:74-5.
Adam R et al. Tumor progression while on chemotherapy: A contraindication to liver
resection for multiple colorectal metastases? Ann Surg 2004;240(6):1052-64. Abstract
Barrier A et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24(29):4685-91. Abstract
Chung KY, Kelsen D. Adjuvant therapy for stage II colorectal cancer: Who and with what? Curr Treat Options Gastroenterol 2006;9(3):272-80. Abstract
Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45. Abstract
Dealis C et al. Phase II trial of FOLFOX-6 and bevacizumab in unresectable liver metastasis from colorectal cancer: A preliminary safety analysis. Gastrointestinal Cancer Symposium 2007;Abstract 452.
Gruenberger B et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. Proc ASCO 2006;Abstract 3546.
Gruenberger T et al. Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Proc ASCO 2006;Abstract 3500.
Hochster HS. Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006;33(5 Suppl 10):8-14. Abstract
Hurwitz HI et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23(15):3502-8. Abstract
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Lenz H et al. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Gastrointestinal Cancer Symposium 2007;Abstract 401.
Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO 2005;Abstract 3508.
Souglakos J et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94(6):798-805. Abstract
Venook A et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc ASCO 2006;Abstract 3509.
Vincenzi B et al. The new era in the treatment of advanced colorectal cancer patients: The role of monoclonal antibodies. Expert Opin Emerg Drugs 2006;11(4):665-83. Abstract
Yoo PS et al. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6(3):202-7. Abstract
